Hengrui Medicine receives approval for HRS9531 clinical trial
Jiangsu Hengrui Medicine (SSE:600276) announced that its subsidiary, Fujian Shengdi Medicine, has received approval from the NMPA for clinical trials of HRS9531 injection, a novel drug indicated for obstructive sleep apnea combined with obesity. HRS9531, a dual GIPR and GLP-1R agonist, aims to modulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity. As of the announcement, the cumulative research and development investment in the HRS9531 project is CNY25,583,000. The company cautioned that the drug's development is subject to regulatory review and market uncertainties, urging investors to exercise caution. Hengrui Medicine will proceed with the project and disclose subsequent progress.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime